Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in metastatic castration-resistant prostate cancer post-docetaxel
NCT00599313Phase 2Completed
- Sponsor
- US Oncology Network
- Start
- Mar 2007
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in metastatic castration-resistant prostate cancer (mCRPC), sponsored by US Oncology Network. Started Mar 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT00599313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00599313.